Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Core Viewpoint - Intellia Therapeutics has temporarily halted dosing and screening of patients in two late-stage studies of its gene-editing treatment for a heart condition following a patient adverse event [1] Group 1: Company Actions - The company announced the temporary suspension of patient dosing and screening in response to an adverse event experienced by a patient [1] - This decision affects two late-stage studies that are critical for the development of the gene-editing treatment [1] Group 2: Implications for Research - The halt in studies may impact the timeline for the treatment's development and potential market entry [1] - Ongoing monitoring and evaluation of the situation will be necessary to determine the next steps for the clinical trials [1]